Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

Amgen licenses neurotrophic agents from Guilford:

This article was originally published in Clinica

  • News

Executive Summary

Amgen has bought the worldwide rights to all human diagnostic and therapeutic applications of Guilford Pharmaceutical's FKBP-neuroimmunophilin ligands, a novel class of small molecule neurotrophic agents. Amgen will pay $35 million initially and $13.5 million over three years to support research at Guilford, plus milestone payments (of up to $392 million) and royalties. Amgen will develop, manufacture and market the products worldwide.

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

Front Line Medical Technologies Announce CE Mark For COBRA-OS

Recalls Round-Up: Class 1s For BioMérieux, Fresenius, Draeger, More

New Guidance For Breast Cancer Screening Drops Age Of First Scan To 40

CDRH’s AR/VR Home Space Will Serve As An ‘Idea Lab’ For Device Stakeholders

See All
UsernamePublicRestriction

Register

MT085827

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By